Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC) , a biopharmaceutical company specializing in the development of a new class of drugs acting directly on the brain to treat difficult-to-treat and resistant hypertension and heart failure, announces the appointment of Benoit Gueugnon as Vice-President Finance.

He succeeds Marc Karako who is leaving office.

A graduate of EM Normandie and holder of a Master II in Audit & Corporate Finance, Benoit brings his solid financial experience to the management team, having a successful experience as Senior Financial Auditor at KPMG Paris. He joined Quantum Genomics in 2018 as Head of Financial Control and worked with Marc Karako whom he replaces.

Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics, wanted to ' thank Benoit, who since his arrival with us in 2018, has demonstrated his enthusiasm and his effectiveness, especially during the implementation of the partnership signed with Biolab. I am very happy to promote him to this strategic position. His energy and skills are real assets for our society. '

Benoit Gueugnon wanted to 'thank Jean-Philippe, the entire management team and the board of directors for this opportunity. I am delighted to continue to support Quantum Genomics, in particular with a view to the start of Phase III in difficult to treat and resistant hypertension, and new partnerships. '

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC) and listed on the American OTCQX market (symbol: QNNTF).

Contact:

Mike Tattory

Tel: +1 (646) 751-4362

Email: mtattory@lifescipublicrelations.com

(C) 2020 Electronic News Publishing, source ENP Newswire